Founded in 2019 and based in New York, TIO Bioventures invests in biotechnology companies and has additional offices in Hong Kong, Boston, and Toronto. The firm's focus is on funding biotech companies that create first-in-class cancer medicines, guided by rigorous research-driven science to improve survival and quality of life. Unlike traditional venture funds, TIO Bioventures uses its internal TIO Discovery and development engine to efficiently drive portfolio companies through key catalysts with a hands-on approach. The TIO Discovery engine provides drug discovery, R&D, and early stage clinical development capabilities to support portfolio companies as they move into further stages of development. The firm takes a control shareholder position in each of its portfolio companies and currently has multiple portfolio companies in development, including Treadwell Therapeutics, a clinical-stage oncology company, a biologics-focused oncology company with lead candidates identified, and a differentiated T cell therapy company.